Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Gastric Cancer

Free Subscription Articles published in Lancet Retrieve available abstracts of 12 articles: HTML format

Single Articles

June 2026
1. SHEN L, Zhang X, Ji K, Lu L, et al
   Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study.
   Lancet. 2026 Jun 1:S0140-6736(26)00974-8. doi: 10.1016/S0140-6736(26)00974.
   PubMed     Abstract available
   
   
   January 2026
2. LIU C, Peng Z, Qi C, Shen L, et al
   Rethinking CLDN18.2 expression in gastric cancer therapy - Authors' reply.
   Lancet. 2026;407:130.
   PubMed    
   
   
   
3. LUO P, Wong HZH, Shan D
   Rethinking CLDN18.2 expression in gastric cancer therapy.
   Lancet. 2026;407:129-130.
   PubMed    
   
   
   November 2025
4. SUNDAR R, Hyun CS, Smyth EC
   Population screening for Helicobacter pylori to reduce gastric cancer - Authors' reply.
   Lancet. 2025;406:2060-2061.
   PubMed    
   
   
   
5. FORD AC, Moayyedi P
   Population screening for Helicobacter pylori to reduce gastric cancer.
   Lancet. 2025;406:2059-2060.
   PubMed    
   
   
   June 2025
6. QI C, Liu C, Peng Z, Zhang Y, et al
   Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
   Lancet. 2025;405:2049-2060.
   PubMed     Abstract available
   
   
   May 2025
7. SUNDAR R, Nakayama I, Markar SR, Shitara K, et al
   Gastric cancer.
   Lancet. 2025 May 1:S0140-6736(25)00052-2. doi: 10.1016/S0140-6736(25)00052.
   PubMed     Abstract available
   
   
   June 2024
8. SINGH S, Halperin D, Myrehaug S, Herrmann K, et al
   [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high?dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomise
   Lancet. 2024;403:2807-2817.
   PubMed     Abstract available
   
   
   
9. LIOU JM, Malfertheiner P, Smith SI, El-Omar EM, et al
   40 years after the discovery of Helicobacter pylori: towards elimination of H pylori for gastric cancer prevention.
   Lancet. 2024;403:2570-2572.
   PubMed    
   
   
   December 2023
10. SMYTH EC, Sundar R
    Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer.
    Lancet. 2023;402:2168-2170.
    PubMed    
    
    
    May 2023
11. SHITARA K, Lordick F, Bang YJ, Enzinger P, et al
    Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 tr
    Lancet. 2023;401:1655-1668.
    PubMed     Abstract available
    
    
    March 2023
12. O'MAHONY D, Power SP, Power DG
    Human epidermal growth factor receptor 2-positive metastatic gastric cancer in complete sustained remission with trastuzumab.
    Lancet. 2023;401:772.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum